Liver cirrhosis profoundly alters drug pharmacokinetics and is frequently associated with medication-related problems in clinical practice. At present，stage-specific medication guidance remains inconsistent，and the information in package inserts often lacks clarity. As a result，treatment decisions rely on individual clinical judgment and differ markedly between different professionals. In 2026，a multidisciplinary expert panel issued recommendation on drug selection and dose adjustment for patients with liver cirrhosis. Using the Delphi method，the suggestion investigates the decisions made by hepatologists，clinical pharmacologists，and clinical pharmacists in terms of drug selection and dose adjustment for liver cirrhosis patients，quantifies the consensus across different Child-Pugh classes，and evaluates the consistency between the recommendations in expert consensus and the information in package inserts，in order to provide a basis for establishing standardized medication guidance. This article gives an excerpt of the main content of the study.